# LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

> **NCT01373086** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** LFF269
- **DRUG:** Eplerenone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01373086
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01373086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01373086, "LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT01373086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*